| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46000597 | BKPyv | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS10012671 | HBV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS10018020 | HBV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS30078329 | HIV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS20020989 | HPV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS20020999 | HPV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS20033273 | HPV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS20020991 | HPV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS20021003 | HPV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
| TVIS20020996 | HPV | ENSG00000066468.24 | protein_coding | FGFR2 | Yes | No | 2263 | A0A141AXF1 D2CGD1 P21802 S4R381 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FGFR2 |
|---|---|
| DrugBank ID | DB09079 |
| Drug Name | Nintedanib |
| Target ID | BE0000748 |
| UniProt ID | P21802 |
| Regulation Type | inhibitor |
| PubMed IDs | 18559524; 31016670 |
| Citations | Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.@@Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C: Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. doi: 10.1007/s40262-019-00766-0. |
| Groups | Approved |
| Direct Classification | Indolecarboxylic acids |
| SMILES | COC(=O)C1=CC=C2C(NC(=O)C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL502835 |
